Cytek Biosciences Inc (CTKB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2020 | 12-2017 | 12-2006 | |
| Assets | |||
| Current Assets | |||
| Cash & Cash Equivalents | 166,119 | N/A | N/A |
| Receivables | 16,990 | N/A | N/A |
| Inventories | 23,018 | N/A | N/A |
| TOTAL | $208,622 | $N/A | $N/A |
| Non-Current Assets | |||
| PPE Net | 2,140 | N/A | N/A |
| Intangibles | 750 | 0 | 0 |
| Other Non-Current Assets | 8,467 | 0 | 0 |
| TOTAL | $11,357 | $N/A | $N/A |
| Total Assets | $219,979 | $N/A | $N/A |
| Liabilities | |||
| Current Liabilities | |||
| Accounts payable and accrued liabilities | 2,944 | 0 | 0 |
| Accrued Expenses | 9,048 | N/A | N/A |
| Other current liabilities | 10,879 | N/A | N/A |
| TOTAL | $26,536 | $N/A | $N/A |
| Non-Current Liabilities | |||
| Deferred Revenues | 3,665 | N/A | N/A |
| Other Non-Current Liabilities | 11,696 | 0 | 0 |
| TOTAL | $15,152 | $N/A | $N/A |
| Total Liabilities | $41,688 | $N/A | $N/A |
| Shareholders' Equity | |||
| Common Shares | 23 | N/A | N/A |
| Retained earnings | -22,607 | N/A | N/A |
| Other shareholders' equity | 194,384 | 0 | 0 |
| TOTAL | $178,291 | $N/A | $N/A |
| Total Liabilities And Equity | $219,979 | $0 | $0 |